Could anti‐hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID‐19 infection? Data from centers of southern Italy

By Sardu C, Maggi P, Messina V, et al
Published September 1, 2020

Key Takeaways

Severe acute respiratory syndrome in coronavirus disease 2019 (COVID‐19) involves binding with target epithelial lung cells through angiotensin‐converting enzyme 2 in humans. Researchers here examined how angiotensin‐converting enzyme (ACE) inhibitors vs angiotensin receptor blockers (ARBs) vs calcium channel blockers (CCBs) drugs affect clinical outcomes in patients with hypertension hospitalized for COVID‐19. Outcomes assessed were mechanical ventilation, intensive care unit admissions, heart injuries and deaths. In this prospectively conducted multicenter study, lowest values of left ventricle ejection fraction were predictive of deaths, while highest values of interleukin‐6 were predictive of the admission to intensive care unit, mechanical ventilation, heart injuries, and deaths. Observations suggest no impact of anti‐hypertensive drugs on the prognosis in patients with COVID‐19. Hence, a worse prognosis can be prevented and an improvement in the clinical outcomes can be attained with providing tailored anti‐inflammatory and immune therapies in addition to chronic antihypertensive therapy to patients with hypertension with COVID‐19 infection.

Read the full article on Journal of the American Heart Association.

Share with emailShare to FacebookShare to LinkedInShare to Twitter